Table 1.
Baseline characteristics of patients (65 patients).
| Characteristics | n | % | |
|---|---|---|---|
| Age, median (range), years | 65 (22–89) | ||
| Sex | Women | 11 | 16.9 |
| Men | 54 | 83.1 | |
| ECOG-PS | 0 | 38 | 58.5 |
| 1 | 26 | 40.0 | |
| 2 | 1 | 1.5 | |
| Child-Pugh Score | 5 | 47 | 72.3 |
| 6 | 11 | 16.9 | |
| 7 | 5 | 7.7 | |
| 8 | 2 | 3.1 | |
| BCLC Stage | A | 1 | 1.5 |
| B | 32 | 49.2 | |
| C | 32 | 49.2 | |
| Etiology | Hepatitis B | 24 | 36.9 |
| Hepatitis C | 6 | 9.2 | |
| NASH | 10 | 15.3 | |
| Alcohol | 3 | 4.6 | |
| Others | 22 | 33.8 | |
| Cirrhosis | Presence | 27 | 41.5 |
| Absence | 38 | 58.5 | |
| Comorbidities | Hypertension | 19 | 29.2 |
| Diabetes | 15 | 23 | |
| CAD | 6 | 9.2 | |
| Others | 13 | 20 | |
| Absence | 38 | 58.5 | |
| Extrahepatic metastasis | Lung | 18 | 27.7 |
| Bone | 10 | 15.4 | |
| Others | 8 | 12.3 | |
| Prior therapy | TACE | 12 | 18.5 |
| TARE | 10 | 15.4 | |
| Histopathology | Presence | 51 | 78.5 |
| Absence | 14 | 21.5 | |
| Antibiotic use | User | 7 | 10.7 |
| Non-user | 58 | 89.3 | |
| AFP, median (range), ng/mL | 80 (1.4–409220) | ||
| Platelets, median (range), 103/μL | 221 (46–481) | ||
| Total bilirubin, median (range), mg/dL | 0.89 (0.19–4) | ||
| Albumin, median (range), g/dL | 3.96 (2.3–4.9) | ||
| INR, median (range) | 1.08 (0.8–1.7) | ||
AFP = alpha-fetoprotein, BCLC = Barcelona Clinic Liver Cancer, CAD = coronary artery disease, ECOG-PS = Eastern Cooperative Oncology Group-Performance Status, INR = international normalized ratio, NASH = nonalcoholic steatohepatitis, TACE = transarterial chemoembolization, TARE = transarterial radioembolization.